|
1
|
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
|
J Clin Oncol
|
2005
|
2.77
|
|
2
|
Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
|
Clin Cancer Res
|
2008
|
1.30
|
|
3
|
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
|
Breast Cancer Res
|
2013
|
1.18
|
|
4
|
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells.
|
Proc Natl Acad Sci U S A
|
2007
|
1.18
|
|
5
|
A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.
|
Sci Signal
|
2013
|
1.04
|
|
6
|
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.
|
Clin Cancer Res
|
2010
|
0.94
|
|
7
|
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
|
Int J Cancer
|
2010
|
0.93
|
|
8
|
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.
|
Breast Cancer Res
|
2012
|
0.87
|